OBJECTIVE: To describe the development and calibration of the banks and scales of the Quality of Life in Neurological Disorders (Neuro-QOL) project, commissioned by the National Institute of Neurological Disorders and Stroke to develop a bilingual (English/Spanish), clinically relevant, and psychometrically robust health-related quality-of-life (HRQOL) assessment tool. DESIGN: Classic and modern test construction methods were used, including input from essential stakeholder groups. SETTING: An online patient panel testing service and 11 academic medical centers and clinics from across the United States and Puerto Rico that treat major neurologic disorders. PARTICIPANTS: Adult and pediatric patients representing different neurologic disorders specified in this study, proxy respondents for select conditions (stroke, pediatric conditions), and English- and Spanish-speaking participants from the general population. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Multiple generic and condition-specific measures used to provide construct validity evidence for the new Neuro-QOL tool. RESULTS: Neuro-QOL has developed 14 generic item banks and 8 targeted scales to assess HRQOL in 5 adult (stroke, multiple sclerosis, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis) and 2 pediatric conditions (epilepsy, muscular dystrophies). CONCLUSIONS: The Neuro-QOL system will continue to evolve, with validation efforts in clinical populations and new bank development in health domains not presently included. The potential for Neuro-QOL measures in rehabilitation research and clinical settings is discussed.
OBJECTIVE: To describe the development and calibration of the banks and scales of the Quality of Life in Neurological Disorders (Neuro-QOL) project, commissioned by the National Institute of Neurological Disorders and Stroke to develop a bilingual (English/Spanish), clinically relevant, and psychometrically robust health-related quality-of-life (HRQOL) assessment tool. DESIGN: Classic and modern test construction methods were used, including input from essential stakeholder groups. SETTING: An online patient panel testing service and 11 academic medical centers and clinics from across the United States and Puerto Rico that treat major neurologic disorders. PARTICIPANTS: Adult and pediatric patients representing different neurologic disorders specified in this study, proxy respondents for select conditions (stroke, pediatric conditions), and English- and Spanish-speaking participants from the general population. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Multiple generic and condition-specific measures used to provide construct validity evidence for the new Neuro-QOL tool. RESULTS: Neuro-QOL has developed 14 generic item banks and 8 targeted scales to assess HRQOL in 5 adult (stroke, multiple sclerosis, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis) and 2 pediatric conditions (epilepsy, muscular dystrophies). CONCLUSIONS: The Neuro-QOL system will continue to evolve, with validation efforts in clinical populations and new bank development in health domains not presently included. The potential for Neuro-QOL measures in rehabilitation research and clinical settings is discussed.
Authors: Stephen M Haley; Wendy J Coster; Patricia L Andres; Larry H Ludlow; Pengsheg Ni; Tamara L Y Bond; Samuel J Sinclair; Alan M Jette Journal: Med Care Date: 2004-01 Impact factor: 2.983
Authors: Bryce B Reeve; Ron D Hays; Jakob B Bjorner; Karon F Cook; Paul K Crane; Jeanne A Teresi; David Thissen; Dennis A Revicki; David J Weiss; Ronald K Hambleton; Honghu Liu; Richard Gershon; Steven P Reise; Jin-shei Lai; David Cella Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: Sarinnapha M Vasunilashorn; Dena Schulman-Green; Douglas Tommet; Tamara G Fong; Tammy T Hshieh; Edward R Marcantonio; Eran D Metzger; Eva M Schmitt; Patricia A Tabloski; Thomas G Travison; Yun Gou; Benjamin Helfand; Sharon K Inouye; Richard N Jones Journal: Dement Geriatr Cogn Disord Date: 2020-06-17 Impact factor: 2.959
Authors: N E Carlozzi; N R Downing; M K McCormack; S G Schilling; J S Perlmutter; E A Hahn; J S Lai; S Frank; K A Quaid; J S Paulsen; D Cella; S M Goodnight; J A Miner; M A Nance Journal: Qual Life Res Date: 2016-07-08 Impact factor: 4.147
Authors: F Biering-Sørensen; S Alai; K Anderson; S Charlifue; Y Chen; M DeVivo; A E Flanders; L Jones; N Kleitman; A Lans; V K Noonan; J Odenkirchen; J Steeves; K Tansey; E Widerström-Noga; L B Jakeman Journal: Spinal Cord Date: 2015-02-10 Impact factor: 2.772
Authors: Elizabeth A Hahn; Nancy R Downing; Julie C Stout; Jane S Paulsen; Becky Ready; Siera Goodnight; Jin-Shei Lai; Jennifer A Miner; Noelle E Carlozzi Journal: Qual Life Res Date: 2017-12-06 Impact factor: 4.147
Authors: Nora E Fritz; Nicholas R Boileau; Julie C Stout; Rebecca Ready; Joel S Perlmutter; Jane S Paulsen; Kimberly Quaid; Stacey Barton; Michael K McCormack; Susan L Perlman; Noelle E Carlozzi Journal: J Neuropsychiatry Clin Neurosci Date: 2018-03-21 Impact factor: 2.198
Authors: N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella Journal: Qual Life Res Date: 2016-08-13 Impact factor: 4.147
Authors: Noelle E Carlozzi; Denise Fyffe; Kel G Morin; Rachel Byrne; David S Tulsky; David Victorson; Jin-Shei Lai; Jill M Wecht Journal: Arch Phys Med Rehabil Date: 2013-03-14 Impact factor: 3.966
Authors: John M Salsman; David Victorson; Seung W Choi; Amy H Peterman; Allen W Heinemann; Cindy Nowinski; David Cella Journal: Qual Life Res Date: 2013-03-23 Impact factor: 4.147